Tofacitinib Shows Greater Effectiveness in Ankylosing Spondylitis Patients with High CRP Levels

Tofacitinib Shows Greater Effectiveness in Ankylosing Spondylitis Patients with High CRP Levels

by | Sep 28, 2024 | Spondyloarthritis, Acute Phase Reactants, Ankylosing Spondylitis, C-reactive Protein, JAK Inhibitor, Tofacitinib

This article presents a post hoc analysis of how baseline (BL) C-Reactive Protein (CRP) levels affect the efficacy and safety of Tofacitinib, a medication used to treat Ankylosing Spondylitis (AS). Tofacitinib is a Janus kinase inhibitor, a type of drug that helps...